期刊
TRANSPLANT INFECTIOUS DISEASE
卷 15, 期 3, 页码 219-232出版社
WILEY
DOI: 10.1111/tid.12054
关键词
influenza; hematopoietic stem cell transplantation; HSCT; leukemia; The European Conference on Infections in Leukemia; ECIL-4; guidelines; recommendations
资金
- Astellas Pharma
- Gilead Sciences
- Merck
- Pfizer
Influenza may cause severe disease and mortality in leukemia patients and in hematopoietic stem cell transplantation recipients. The 4th European Conference of Infections in Leukemia (ECIL-4) has developed evidence-based guidelines for prevention and management of influenza infections in these patients. Real-time reverse-transcription polymerase chain reaction is the diagnostic test of choice, as it is the most sensitive and specific test for influenza. The risks for severe influenza and fatal outcome include lymphopenia, older age, influenza soon after transplantation or chemotherapy, steroid treatment, and lack of early antiviral therapy. Neuraminidase inhibitors (oral oseltamivir or inhalation of zanamivir) are currently the most effective therapeutic agents for influenza. Main preventive measures include annual vaccination of patients, household contacts, and hospital staff. This review summarizes ECIL-4's main recommendations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据